An oral SARS-CoV-2 M
pro
inhibitor clinical candidate for the treatment of COVID-19
Author:
Owen Dafydd R.1ORCID, Allerton Charlotte M. N.1ORCID, Anderson Annaliesa S.2, Aschenbrenner Lisa3, Avery Melissa3, Berritt Simon3ORCID, Boras Britton4ORCID, Cardin Rhonda D.2, Carlo Anthony3, Coffman Karen J.3ORCID, Dantonio Alyssa3, Di Li3ORCID, Eng Heather3ORCID, Ferre RoseAnn4ORCID, Gajiwala Ketan S.4, Gibson Scott A.5, Greasley Samantha E.4ORCID, Hurst Brett L.5ORCID, Kadar Eugene P.3ORCID, Kalgutkar Amit S.1ORCID, Lee Jack C.3, Lee Jisun3ORCID, Liu Wei4, Mason Stephen W.2, Noell Stephen3ORCID, Novak Jonathan J.3ORCID, Obach R. Scott3ORCID, Ogilvie Kevin3, Patel Nandini C.1ORCID, Pettersson Martin1ORCID, Rai Devendra K.2, Reese Matthew R.3ORCID, Sammons Matthew F.1ORCID, Sathish Jean G.2, Singh Ravi Shankar P.1ORCID, Steppan Claire M.3ORCID, Stewart Al E.4, Tuttle Jamison B.1, Updyke Lawrence1, Verhoest Patrick R.1, Wei Liuqing3, Yang Qingyi1, Zhu Yuao2
Affiliation:
1. Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA. 2. Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA. 3. Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA. 4. Pfizer Worldwide Research, Development & Medical, La Jolla, CA 92121, USA. 5. Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University; Logan, UT 84322, USA.
Abstract
Path to another drug against COVID-19
The rapid development of vaccines has been crucial in battling the ongoing COVID-19 pandemic. However, access challenges remain, breakthrough infections occur, and emerging variants present increased risk. Developing antiviral therapeutics is therefore a high priority for the treatment of COVID-19. Some drug candidates in clinical trials act against the viral RNA-dependent RNA polymerase, but there are other viral enzymes that have been considered good targets for inhibition by drugs. Owen
et al
. report the discovery and characterization of a drug against the main protease involved in the cleavage of polyproteins involved in viral replication. The drug, PF-07321332, can be administered orally, has good selectivity and safety profiles, and protects against infection in a mouse model. In a phase 1 clinical trial, the drug reached concentrations expected to inhibit the virus based on in vitro studies. It also inhibited other coronaviruses, including severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome coronavirus, and could be in the armory against future viral threats. —VV
Publisher
American Association for the Advancement of Science (AAAS)
Subject
Multidisciplinary
Cited by
1050 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Betacoronavirus Infection Outbreak, São Paulo, Brazil, Fall 2023;Emerging Infectious Diseases;2024-03 2. Recent Discovery of Peptidomimetics for the Treatment of Coronavirus
(COVID-19), Human Coronavirus, and Enteroviruses;Current Medicinal Chemistry;2024-03 3. The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19;Pharmaceutics;2024-02-02 4. Structure-property Relationships Reported for the New Drugs Approved
in 2022;Mini-Reviews in Medicinal Chemistry;2024-02 5. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study;The Lancet Infectious Diseases;2024-02
|
|